US › Healthcare

Aptevo Therapeutics Inc (APVO)

US · Healthcare · Biotechnology

$1.62-4.71%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.4M

EPS

$-5.31

EPS estimate

$-6.02

EPS came in at -5.31 against a street estimate of -6.02 — a beat of 11.8%.

Key statistics

Market cap

$3.2M

P/E

0.0

Forward P/E

3.9

P/B

0.57

Book value

$4.26

EPS (TTM)

$66.96

52-week high

$30.06

52-week low

$1.37

50-day MA

$2.46

200-day MA

$5.03

Beta

1.68

Analyst view

Analysts rate Aptevo Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $25.50.

Shareholding

Insiders

4.15%

Institutions

2.88%

Largest institutional holders

Fund	Stake
GSA Capital Partners LLP	1.19%
Vanguard Capital Management, LLC	0.70%
Geode Capital Management, LLC	0.60%
Vanguard Fiduciary Trust Co	0.23%
UBS Group AG	0.04%
Advisor Group Holdings, Inc.	0.02%
SBI Securities Co Ltd	0.01%
Barclays PLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aptevo Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.